

THE ORTHO CLINICAL DIAGNOSTICS FRANCHISE



About the Ortho Clinical Diagnostics Franchise

With as much as 70 percent of healthcare decisions influenced by diagnostic test results, diagnostics play a major role in healthcare and patient outcomes.^{1,2} In the future, diagnostics will be the common denominator underlying the entire patient care process — from predicting and preventing diseases to guiding therapy and surgical decisions.

Ortho Clinical Diagnostics (OCD) is one of seven franchises that are a part of the Johnson & Johnson Medical Device and Diagnostic Companies, the world's largest medical technology business. The OCD franchise is a fully integrated, global business comprised of instruments and tests for transfusion medicine and clinical laboratories, biomarkers and cellular therapies, and lean consulting services. The franchise is committed to bringing products to market that can help identify illnesses more rapidly, leading to patient care and treatment that will hopefully help to avoid progression to more serious disorders. OCD's products allow people to be healthier by predicting disease before a person's life may be at risk; providing effective treatments to help people feel better; and introducing medical breakthroughs and innovations so that people can live longer lives.

The OCD franchise is committed to enabling diagnostics to fulfill its important role in the continuum of care and changing the focus of healthcare from treating sickness to promoting wellness. Through investments in valuable medical content and new growth platforms, OCD aims to enable diagnostics to take on an even more important role in predicting and ultimately reducing chronic illness.

Three businesses within the OCD franchise develop and commercialize a variety of products to meet the changing needs of physicians and patients:

Ortho Clinical Diagnostics is a leading provider of *in vitro* diagnostic products and services, offering accurate, timely, and cost-effective solutions for screening, diagnosing, monitoring and confirming diseases. The company serves the global clinical laboratory and transfusion medicine community, and is committed to providing customers with products, services and process solutions to make labs more efficient in delivering the quality test results doctors and patients need. OCD's ValuMetrix® Consulting Service benefits a range of patient care providers by helping maximize their effectiveness through benchmarking, optimization processes and other valuable consulting services to achieve operational improvements. Furthermore, OCD pioneered the Remote Monitoring Center – an industry-first, 24-7 central command center that uses predictive alerts from instruments to detect and predict potential problems up to 30 days in advance, before they interrupt the ability of the laboratory to deliver quality results.

Veridex is an organization dedicated to providing physicians with high-value diagnostic oncology products. Veridex's *in vitro* diagnostic products may significantly benefit patients by helping physicians make more informed decisions that enable better patient care. Veridex's Clinical Research Solutions provide tools and services that may be used for the selection, identification and enumeration of targeted rare cells in peripheral blood for the identification of biomarkers, aiding scientists in their search for new, targeted therapies.

Therakos markets the world's only currently approved integrated systems for extracorporeal photopheresis (ECP). ECP is an innovative cellular therapy that treats the palliative skin manifestations of Cutaneous T-Cell Lymphoma (CTCL) that are unresponsive to other therapies. CTCL is a slow-growing non-Hodgkin's lymphoma that affects an estimated 16,000 to 20,000 people across the United States.³

*THERAKOS™ UVAR™ XTS™ and CELLEX™ Systems are also available in Canada and the European Union.

Important Safety Information

UVADEX™ (methoxsalen) Sterile Solution is indicated for extracorporeal administration with the THERAKOS™ UVAR™ XTS or THERAKOS™ CELLEX™ Photopheresis System in the palliative treatment of the skin manifestations of cutaneous T-cell lymphoma (CTCL) that is unresponsive to other forms of treatment.

Methoxsalen is not appropriate for patients who have had a reaction to psoralen compounds, patients who have had a light sensitive disease, or patient with an absence of one or both lenses of the eye.

THERAKOS™ Photopheresis is not appropriate for patients who cannot tolerate blood volume changes or patients with blood clotting disorders. The most commonly reported adverse event is transient non-serious hypotension (a drop in blood pressure) due to minor changes in blood volume during treatment. Other potential side effects such as fever or skin redness usually go away within one day. For more information visit www.therakos.com.

Worldwide Locations

The Ortho Clinical Diagnostics franchise is headquartered in Raritan, NJ, with operations in Rochester, NY, Huntingdon Valley, PA, Pompano Beach, FL, Strasbourg, France and Pencoed, Wales. The franchise has more than 3,000 employees worldwide.

For more information, visit:

Ortho-Clinical Diagnostics, Inc.
www.orthoclinical.com

Therakos, Inc.
www.therakos.com

Veridex, LLC
www.veridex.com

¹The Lewin Group, 2005. The Value of Diagnostics: Innovation, Adoption and Diffusion into Health Care.

²*Managed Care*, 2009. Emad Rizk, M.D. Molecular Diagnostic Testing Presents \$5 Billion Conundrum.

³ Cutaneous Lymphoma Foundation. *CTCL-MG Fast Facts*, p.2